Published in Arthritis Rheum on June 01, 2003
Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis (2007) 4.05
Interleukin-6 and its receptor: from bench to bedside. Med Microbiol Immunol (2006) 1.65
Detection of protein biomarkers using RNA aptamer microarrays and enzymatically amplified surface plasmon resonance imaging. Anal Chem (2007) 1.56
Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis (2007) 1.44
The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis. Arthritis (2011) 1.33
Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases. Int J Biol Sci (2012) 1.27
IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol (2014) 1.27
Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology (Oxford) (2009) 1.24
The many faces of interleukin-6: the role of IL-6 in inflammation, vasculopathy, and fibrosis in systemic sclerosis. Int J Rheumatol (2011) 1.24
Changes in biochemical parameters after anterior cruciate ligament injury. Int Orthop (2005) 1.17
New insights in synovial angiogenesis. Joint Bone Spine (2009) 1.12
Aryl hydrocarbon receptor (AhR) agonists suppress interleukin-6 expression by bone marrow stromal cells: an immunotoxicology study. Environ Health (2003) 1.11
Auranofin blocks interleukin-6 signalling by inhibiting phosphorylation of JAK1 and STAT3. Immunology (2007) 1.10
Vascular endothelial growth factor (VEGF) in autoimmune diseases. J Clin Immunol (2007) 1.02
Subtoxic levels hydrogen peroxide-induced production of interleukin-6 by retinal pigment epithelial cells. Mol Vis (2010) 1.02
Interleukin 6 and rheumatoid arthritis. Biomed Res Int (2014) 1.00
The varying faces of IL-6: From cardiac protection to cardiac failure. Cytokine (2015) 0.98
T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritis. Arthritis Res Ther (2008) 0.97
IL-6/sIL-6R trans-signalling, but not TNF-alpha induced angiogenesis in a HUVEC and synovial cell co-culture system. Rheumatol Int (2009) 0.97
The vasculature in rheumatoid arthritis: cause or consequence? Int J Exp Pathol (2009) 0.97
Immature blood vessels in rheumatoid synovium are selectively depleted in response to anti-TNF therapy. PLoS One (2009) 0.96
Rheumatoid arthritis-associated gene-gene interaction network for rheumatoid arthritis candidate genes. BMC Proc (2009) 0.96
Anti-inflammatory mechanism of tocilizumab, a humanized anti-IL-6R antibody: effect on the expression of chemokine and adhesion molecule. Rheumatol Int (2009) 0.95
Comparative evaluation of the effects of treatment with tocilizumab and TNF-α inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients. Arthritis Res Ther (2013) 0.95
Angiogenesis in rheumatoid arthritis. Autoimmunity (2009) 0.95
Regulation of a lymphocyte-endothelial-IL-6 trans-signaling axis by fever-range thermal stress: hot spot of immune surveillance. Cytokine (2007) 0.94
The role of interleukin 6 in the pathophysiology of rheumatoid arthritis. Ther Adv Musculoskelet Dis (2010) 0.92
The pathogenic role of angiogenesis in rheumatoid arthritis. Angiogenesis (2015) 0.91
Vascular endothelial growth factor blockade reduces plasma cytokines in a murine model of polymicrobial sepsis. Inflammation (2004) 0.91
Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions. Int J Rheumatol (2012) 0.89
Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease. Graefes Arch Clin Exp Ophthalmol (2010) 0.88
Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord (2012) 0.87
Current perspectives on tocilizumab for the treatment of rheumatoid arthritis: a review. Patient Prefer Adherence (2013) 0.86
Interleukin-6 blockade in ocular inflammatory diseases. Clin Exp Immunol (2014) 0.84
Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling. MAbs (2014) 0.84
Macrophages and angiogenesis in rheumatic diseases. Vasc Cell (2013) 0.84
Comprehensive evaluation of different T-helper cell subsets differentiation and function in rheumatoid arthritis. J Biomed Biotechnol (2012) 0.83
Targeting VEGF and Its Receptors for the Treatment of Osteoarthritis and Associated Pain. J Bone Miner Res (2016) 0.83
Thalidomide for tocilizumab-resistant ascites with TAFRO syndrome. Clin Case Rep (2015) 0.83
Anti-TNF-alpha antibody Infliximab and glucocorticoids reduce serum vascular endothelial growth factor levels in patients with rheumatoid arthritis: a pilot study. Rheumatol Int (2005) 0.82
Treatment with the arginase inhibitor Nw-hydroxy-nor-L-arginine restores endothelial function in rat adjuvant-induced arthritis. Arthritis Res Ther (2012) 0.82
Targeting the synovial angiogenesis as a novel treatment approach to osteoarthritis. Ther Adv Musculoskelet Dis (2014) 0.82
Early intervention in the treatment of rheumatoid arthritis: focus on tocilizumab. Ther Clin Risk Manag (2013) 0.81
Review of tocilizumab in the treatment of rheumatoid arthritis. Biologics (2008) 0.81
Aryl hydrocarbon receptor antagonism attenuates growth factor expression, proliferation, and migration in fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Pharmacol Exp Ther (2013) 0.81
Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman Disease and is associated with increased soluble interleukin-6 receptor levels. PLoS One (2013) 0.81
Over-expression of extracellular superoxide dismutase in mouse synovial tissue attenuates the inflammatory arthritis. Exp Mol Med (2012) 0.81
Histological analysis of synovium in cases of effect attenuation associated with infliximab therapy in rheumatoid arthritis. Clin Rheumatol (2008) 0.80
Transglutaminase 2 cross-linking activity is linked to invadopodia formation and cartilage breakdown in arthritis. Arthritis Res Ther (2012) 0.80
Extracellular matrix modulates angiogenesis in physiological and pathological conditions. Biomed Res Int (2014) 0.80
Management of rheumatoid arthritis in People's Republic of China - focus on tocilizumab and patient considerations. Int J Gen Med (2015) 0.80
Inflammation induced loss of skeletal muscle. Bone (2015) 0.79
Endothelial Dysfunction and Inflammation: Immunity in Rheumatoid Arthritis. Mediators Inflamm (2016) 0.79
Gene expression of catabolic inflammatory cytokines peak before anabolic inflammatory cytokines after ACL injury in a preclinical model. J Inflamm (Lond) (2014) 0.78
Does vascular endothelial growth factor play a role in interleukin-6 receptor antagonist therapy for rheumatoid arthritis? Arthritis Rheum (2003) 0.78
The macrophages in rheumatic diseases. J Inflamm Res (2016) 0.78
Pretreatment Prediction of Individual Rheumatoid Arthritis Patients' Response to Anti-Cytokine Therapy Using Serum Cytokine/Chemokine/Soluble Receptor Biomarkers. PLoS One (2015) 0.76
The "genomic storm" induced by bacterial endotoxin is calmed by a nuclear transport modifier that attenuates localized and systemic inflammation. PLoS One (2014) 0.76
Improvement of Aptamer Affinity by Dimerization. Sensors (Basel) (2008) 0.76
Methotrexate as combination partner of TNF inhibitors and tocilizumab. What is reasonable from an immunological viewpoint? Clin Rheumatol (2015) 0.75
Spotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to date. Drug Des Devel Ther (2016) 0.75
A Comprehensive Gene Expression Meta-analysis Identifies Novel Immune Signatures in Rheumatoid Arthritis Patients. Front Immunol (2017) 0.75
Idiopathic remitting seronegative symmetrical synovitis with pitting edema syndrome associated with bilateral pleural and pericardial effusions: a case report. J Med Case Rep (2016) 0.75
Tocilizumab in the treatment of systemic juvenile idiopathic arthritis. Open Access Rheumatol (2012) 0.75
The Role of Angiogenesis in Haemophilic Arthropathy: Where Do We Stand and Where Are We Going? Turk J Haematol (2016) 0.75
Increased levels of IL-6, sIL-6R, and sgp130 in the aqueous humor and serum of patients with diabetic retinopathy. Mol Vis (2016) 0.75
Overexpression of soluble RAGE in mesenchymal stem cells enhances their immunoregulatory potential for cellular therapy in autoimmune arthritis. Sci Rep (2016) 0.75
Concerns in reporting of serum vascular endothelial growth factor levels: comment on the article by Nakahara et al. Arthritis Rheum (2004) 0.75
Role of aryl hydrocarbon receptor in mesenchymal stromal cell activation: A minireview. World J Stem Cells (2017) 0.75
Monitoring of therapeutic efficacy in a patient with RS₃PE syndrome by serologic variables and radiographic methods. Rheumatol Int (2009) 0.75
IL-6 blockade in the management of non-infectious uveitis. Clin Rheumatol (2017) 0.75
[Methotrexate as combination partner of TNF inhibitors and tocilizumab: what is reasonable from an immunological viewpoint?]. Z Rheumatol (2013) 0.75
TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity (2004) 4.48
Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood (2005) 4.29
Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol (2006) 4.10
Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis (2007) 4.05
Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum (2004) 3.92
IL-6: regulator of Treg/Th17 balance. Eur J Immunol (2010) 3.82
SOCS-1 participates in negative regulation of LPS responses. Immunity (2002) 3.39
Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells. Proc Natl Acad Sci U S A (2008) 3.34
Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol (2004) 3.28
The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo. J Clin Invest (2005) 2.91
A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology (2004) 2.75
Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum (2005) 2.64
IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (2008) 2.60
CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res (2013) 2.57
Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc Natl Acad Sci U S A (2010) 2.46
IL-6-dependent and -independent pathways in the development of interleukin 17-producing T helper cells. Proc Natl Acad Sci U S A (2007) 2.46
A primate-specific, brain isoform of KCNH2 affects cortical physiology, cognition, neuronal repolarization and risk of schizophrenia. Nat Med (2009) 2.37
The paradigm of IL-6: from basic science to medicine. Arthritis Res (2002) 2.34
Genetic dissection of the role of catechol-O-methyltransferase in cognition and stress reactivity in mice. J Neurosci (2008) 2.08
Aryl hydrocarbon receptor in combination with Stat1 regulates LPS-induced inflammatory responses. J Exp Med (2009) 2.02
Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol (2005) 1.92
Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation. Clin Cancer Res (2010) 1.84
Therapeutic targeting of the interleukin-6 receptor. Annu Rev Pharmacol Toxicol (2011) 1.76
IgG1 B cell receptor signaling is inhibited by CD22 and promotes the development of B cells whose survival is less dependent on Ig alpha/beta. J Exp Med (2007) 1.75
Suppressor of cytokine signalling-1 gene silencing in acute myeloid leukaemia and human haematopoietic cell lines. Br J Haematol (2004) 1.70
Impaired colonization of the gonads by primordial germ cells in mice lacking a chemokine, stromal cell-derived factor-1 (SDF-1). Proc Natl Acad Sci U S A (2003) 1.69
Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol (2003) 1.69
The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. Neoplasia (2013) 1.58
IL-6 transgenic mouse model for extraosseous plasmacytoma. Proc Natl Acad Sci U S A (2002) 1.55
Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. Arthritis Rheum (2008) 1.55
Autocrine purinergic receptor signaling is essential for macrophage chemotaxis. Sci Signal (2010) 1.52
Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: the JMAAV study. Mod Rheumatol (2011) 1.52
Inhibition of IL-6 for the treatment of inflammatory diseases. Curr Opin Pharmacol (2004) 1.52
Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Arthritis Rheum (2009) 1.51
Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther (2005) 1.48
Essential role of STAT3 in cytokine-driven NF-kappaB-mediated serum amyloid A gene expression. Genes Cells (2005) 1.46
Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomerase. Arthritis Rheum (2008) 1.43
Expression of the suppressor of cytokine signaling-5 (SOCS5) negatively regulates IL-4-dependent STAT6 activation and Th2 differentiation. Proc Natl Acad Sci U S A (2002) 1.42
Suppressor of cytokine signaling-1 selectively inhibits LPS-induced IL-6 production by regulating JAK-STAT. Proc Natl Acad Sci U S A (2005) 1.39
Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer. Cancer Res (2008) 1.35
Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice. Cytokine (2002) 1.34
Cardiac-specific activation of signal transducer and activator of transcription 3 promotes vascular formation in the heart. J Biol Chem (2001) 1.33
Contribution of Toll-like receptor/myeloid differentiation factor 88 signaling to murine liver regeneration. Hepatology (2005) 1.33
Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis (2012) 1.33
Value of serum IgG4 in the diagnosis of IgG4-related disease and in differentiation from rheumatic diseases and other diseases. Mod Rheumatol (2011) 1.33
The influence of excessive IL-6 production in vivo on the development and function of Foxp3+ regulatory T cells. J Immunol (2010) 1.30
Hyperhomocysteinemia promotes inflammatory monocyte generation and accelerates atherosclerosis in transgenic cystathionine beta-synthase-deficient mice. Circulation (2009) 1.30
Robust acinar cell transgene expression of CreErT via BAC recombineering. Genesis (2008) 1.30
Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases. Int J Biol Sci (2012) 1.27
Clinical value of blocking IL-6 receptor. Curr Opin Rheumatol (2009) 1.25
Characterization of anti-mouse interleukin-6 receptor antibody. Immunol Lett (2002) 1.25
IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system. Biochem Biophys Res Commun (2004) 1.25
Hepatoma-derived growth factor stimulates cell growth after translocation to the nucleus by nuclear localization signals. J Biol Chem (2001) 1.23
Suppressor of cytokine signaling-1 ameliorates dextran sulfate sodium-induced colitis in mice. Int Immunol (2008) 1.20
Epidermal loss of JunB leads to a SLE phenotype due to hyper IL-6 signaling. Proc Natl Acad Sci U S A (2009) 1.20
Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas. Int J Cancer (2006) 1.19
iTRAQ-based proteomic identification of leucine-rich alpha-2 glycoprotein as a novel inflammatory biomarker in autoimmune diseases. Ann Rheum Dis (2009) 1.19
A genome-wide association study identified AFF1 as a susceptibility locus for systemic lupus eyrthematosus in Japanese. PLoS Genet (2012) 1.17
The value of blocking IL-6 outside of rheumatoid arthritis: current perspective. Curr Opin Rheumatol (2011) 1.17
Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells. Biochem Biophys Res Commun (2008) 1.16
Sialoadhesin-positive macrophages bind regulatory T cells, negatively controlling their expansion and autoimmune disease progression. J Immunol (2009) 1.16
Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. Ann Rheum Dis (2012) 1.13
Nanosized As2O3/Fe2O3 complexes combined with magnetic fluid hyperthermia selectively target liver cancer cells. World J Gastroenterol (2009) 1.13
Anti-IL-6 receptor monoclonal antibody inhibits leukocyte recruitment and promotes T-cell apoptosis in a murine model of Crohn's disease. J Gastroenterol (2002) 1.13
Underexpression of mitochondrial-DNA encoded ATP synthesis-related genes and DNA repair genes in systemic lupus erythematosus. Arthritis Res Ther (2011) 1.13
Masked early symptoms of pneumonia in patients with rheumatoid arthritis during tocilizumab treatment: a report of two cases. Mod Rheumatol (2008) 1.12
STAT3 mediates cardioprotection against ischemia/reperfusion injury through metallothionein induction in the heart. Cardiovasc Res (2005) 1.11
Endothelial basement membrane laminin alpha5 selectively inhibits T lymphocyte extravasation into the brain. Nat Med (2009) 1.10
Genome-wide identification and expression analysis of rice cell cycle genes. Plant Mol Biol (2007) 1.10
Prevalence and risk factors of overactive bladder syndrome in Fuzhou Chinese women. Neurourol Urodyn (2006) 1.10
Growth and differentiation of rat bone marrow stromal cells: does 5-azacytidine trigger their cardiomyogenic differentiation? Cardiovasc Res (2003) 1.09
Aryl hydrocarbon receptor-mediated induction of the microRNA-132/212 cluster promotes interleukin-17-producing T-helper cell differentiation. Proc Natl Acad Sci U S A (2013) 1.09
A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol (2007) 1.09
Transcriptional complex formation of c-Fos, STAT3, and hepatocyte NF-1 alpha is essential for cytokine-driven C-reactive protein gene expression. J Immunol (2008) 1.08
The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology (Oxford) (2010) 1.08